A detailed history of Legacy Financial Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Legacy Financial Advisors, Inc. holds 2,423 shares of VRTX stock, worth $1.15 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
2,423
Previous 2,306 5.07%
Holding current value
$1.15 Million
Previous $963,000 17.86%
% of portfolio
0.22%
Previous 0.19%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $45,958 - $56,807
117 Added 5.07%
2,423 $1.14 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $59,930 - $65,573
147 Added 6.81%
2,306 $963,000
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $79,576 - $95,277
232 Added 12.04%
2,159 $878,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $127,155 - $136,284
376 Added 24.24%
1,927 $670,000
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $51,250 - $57,361
163 Added 11.74%
1,551 $545,000
Q1 2023

May 03, 2023

BUY
$283.23 - $323.1 $26,057 - $29,725
92 Added 7.1%
1,388 $437,000
Q4 2022

Feb 06, 2023

BUY
$285.76 - $321.48 $7,429 - $8,358
26 Added 2.05%
1,296 $374,000
Q3 2022

Nov 09, 2022

BUY
$273.83 - $305.53 $31,764 - $35,441
116 Added 10.05%
1,270 $368,000
Q2 2022

Aug 08, 2022

BUY
$234.96 - $292.55 $39,943 - $49,733
170 Added 17.28%
1,154 $325,000
Q1 2022

May 04, 2022

BUY
$221.42 - $260.97 $217,877 - $256,794
984 New
984 $257,000
Q2 2019

Aug 07, 2019

SELL
$164.61 - $190.37 $24,526 - $28,365
-149 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $3,765 - $4,478
23 Added 18.25%
149 $27,000
Q4 2018

Jan 16, 2019

BUY
$151.91 - $192.21 $17,621 - $22,296
116 Added 1160.0%
126 $21,000
Q2 2018

Jul 17, 2018

SELL
$145.72 - $169.96 $6,265 - $7,308
-43 Reduced 81.13%
10 $2,000
Q1 2018

Apr 12, 2018

BUY
$151.6 - $177.13 $7,276 - $8,502
48 Added 960.0%
53 $8,000
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $686 - $777
5
5 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Legacy Financial Advisors, Inc. Portfolio

Follow Legacy Financial Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legacy Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Legacy Financial Advisors, Inc. with notifications on news.